The ability of estrogen to prevent glucocorticoid-induced apoptosis in osteoblasts was studied both in vitro and in vivo. Glucocorticoid treatment for 72 h produced a dose-dependent increase in the number of apoptotic cells, determined by acridine orange/ethidium bromide staining, with a maximal response of 31 Ϯ 2% and 26 Ϯ 3% with 100 nM corticosterone in primary rat and mouse osteoblasts, respectively. Simultaneous administration of varying concentrations of 17␤-estradiol and 100 nM corticosterone decreased apoptotic osteoblasts in a dose-dependent manner, with a maximal decrease of 70% with 0.01 nM 17␤-estradiol. Terminal deoxynucleotidyltransferase-mediated deoxy-UTP-biotin nick end labeling also demonstrated glucocorticoidinduced DNA fragmentation that was inhibited by estrogen. Estrogen was shown to inhibit apoptosis induced by lipopolysaccharide treatment. As early as 6 h, Western blots demonstrated a dose-dependent decrease in the Bcl-2/Bax ratio, which reached a minimum of 0.18 in osteoblasts treated with 1000 nM corticosterone for 72 h. This reduction in Bcl-2/Bax was abolished by treating osteoblasts simultaneously with 17␤-estradiol, but not with 17␣-estradiol. In 7-day-old mice, administration of varying concentrations of dexamethasone for 72 h resulted in a dose-dependent increase in the number of apoptotic osteoblasts as demonstrated by in situ terminal deoxynucleotidyltransferase-mediated deoxy-UTP-biotin nick end labeling staining of calvaria. A maximum of 22 Ϯ 1% apoptotic osteoblasts on the bone surface was found with 1 mg/kg BW dexamethasone compared with 2 Ϯ 1% in vehicle-treated mice. Injection of varying concentrations of 17␤-estradiol (0.5-5 mg/kg BW), but not 17␣-estradiol, with 1 mg/kg dexamethasone produced a dose-dependent decrease in the number of apoptotic osteoblasts to 5 Ϯ 1% with 5 mg/kg 17␤-estradiol. Thus, glucocorticoid-induced apoptosis of osteoblasts may be prevented at least in part by
osteoblasts treated with 1000 nM corticosterone for 72 h. This reduction in Bcl-2/Bax was abolished by treating osteoblasts simultaneously with 17␤-estradiol, but not with 17␣-estradiol. In 7-day-old mice, administration of varying concentrations of dexamethasone for 72 h resulted in a dose-dependent increase in the number of apoptotic osteoblasts as demonstrated by in situ terminal deoxynucleotidyltransferase-mediated deoxy-UTP-biotin nick end labeling staining of calvaria. A maximum of 22 Ϯ 1% apoptotic osteoblasts on the bone surface was found with 1 mg/kg BW dexamethasone compared with 2 Ϯ 1% in vehicle-treated mice. Injection of varying concentrations of 17␤-estradiol (0.5-5 mg/kg BW), but not 17␣-estradiol, with 1 mg/kg dexamethasone produced a dose-dependent decrease in the number of apoptotic osteoblasts to 5 Ϯ 1% with 5 mg/kg 17␤-estradiol. Thus, glucocorticoid-induced apoptosis of osteoblasts may be prevented at least in part by 17␤-estradiol. (Endocrinology 140: 5339 -5347, 1999) H YPERCORTISOLISM results in bone loss and is mainly associated with decreased bone formation (1, 2) . In patients receiving glucocorticoid therapy for the management of rheumatic arthritis, asthma, and collagen vascular diseases, yearly bone loss can range from 0.6 -6%/yr, resulting in glucocorticoid-induced osteoporosis (3, 4) . Approximately 50% of patients with Cushing's syndrome and 30 -50% of patients taking long term glucocorticoids have at least one atraumatic fracture due to osteopenia (5, 6) . Histological studies reveal that glucocorticoid treatment can lead to a decrease in the number of osteoid seams, a low mineral apposition rate, and an increase in bone resorption markers (2) .
Estrogen deficiency also has marked effects on bone metabolism and results in osteoporosis (1, (7) (8) (9) . Estrogen withdrawal primarily causes enhanced bone resorption (10, 11) . Estrogen depletion after menopause is strongly associated with a reduction in bone mass and is often accompanied by a remodeling imbalance (12) . Osteoclastic activity is enhanced with an impaired ability of osteoblasts to refill osteoclastic resorption spaces (9) . However, estrogen replacement therapy can prevent bone loss in postmenopausal women (13) .
Many of the in vivo effects of glucocorticoids and estrogen on bone formation have been confirmed by in vitro studies.
In bones cultured for 24 h, glucocorticoids stimulate collagen synthesis, but at later time points glucocorticoids inhibit collagen, fibronectin and DNA synthesis (14 -16) . In cultured rat osteoblastic cells, glucocorticoids inhibit cell replication and DNA content (17) . In contrast, estrogen increases DNA content and alkaline phosphatase activity in osteoblastic cells (18) . Estrogens also stimulate messenger RNA levels for ␣1(I) procollagen and synthesis of type I collagen (19) , which is associated with an increase in insulin-like growth factor I and II secretion (20) . In vivo data in mice and rats demonstrate differences in the response of bone to glucocorticoids. In rats, numerous investigators have found decreased bone formation parameters and bone mass (21) (22) (23) . However, a few studies have shown decreased bone formation without a decrease in bone mass mainly due to effects of glucocorticoids on cartilage and bone resorption (24, 25) . In mice, a decrease in bone mass appears to result from decreased bone formation (26, 27) .
Another mechanism by which glucocorticoids and estrogen may affect osteoblast function is through the control of programmed cell death. Glucocorticoids have been shown to decrease the number of osteoblasts and osteocytes by apoptosis (28 -30) . Glucocorticoids also induce apoptosis in mouse thymocytes and lymphocytes by a receptor-mediated process (31) . Apoptosis is a form of cell death in which the cell actively triggers an intrinsic suicide mechanism that results in cell shrinkage, blebbing of the plasma membrane followed by chromatin condensation, DNA fragmentation, and formation of apoptotic bodies. The apoptotic bodies are rapidly phagocytosed by neighboring cells and macrophages without the release of intracellular contents, and thus, there is no inflammation. In contrast to glucocorticoids, estrogen prevents apoptosis in ovarian granulosa cells (32) and decreases apoptosis of peripheral blood mononuclear cells (33) . In bone, estrogen has been shown to induce apoptosis of osteoclasts (34, 35) , but estrogen's effects on osteoblast apoptosis has not been studied.
As glucocorticoids and estrogen appear to have opposite effects on cell survival, and osteoblasts have glucocorticoid and estrogen receptors that can directly modulate osteoblast gene expression (36 -38) , we hypothesized that estrogen may be able to prevent glucocorticoid-induced apoptosis in bone. To determine which factors and genes are involved in osteoblast apoptotic pathways, osteoblast cultures were examined for Bcl-2 and Bax, which are related proteins associated with apoptosis (39) . Expression of Bcl-2 protein can prevent programmed cell death induced by a variety of stimuli, including growth factor depletion, stress and many chemotherapeutic agents. Expression of Bcl-2 in murine T cell lines and lymphoma cell lines protects these cells from glucocorticoid-induced apoptosis (40, 41) . Bax promotes apoptosis, and Bcl-2 protects cells from programmed cell death. Bcl-2 can form homodimers or heterodimers with Bax (Bcl-2-associated X protein). When the level of Bax increases, Bax homodimers predominate, and cells undergo apoptosis (42) . When Bcl-2 is in excess, Bcl-2 homodimers predominate, and cells survive. This study demonstrates that glucocorticoids and estrogen alter Bcl-2 and Bax levels in osteoblasts. Estrogen is shown to prevent glucocorticoid-induced apoptosis, both in vitro and in vivo.
Materials and Methods

Cell culture
Pregnant Sprague Dawley rats were purchased from Charles River Laboratories, Inc. (Wilmington, MA). Calvaria were removed from 20-day-old fetuses, washed in F-12 medium (Life Technologies, Inc., Gaithersburg, MD), and minced with scissors. Fibroblasts (fraction 1, F1) and osteoblasts (fraction 3, F3) were obtained by sequential digestion of the calvaria with 0.2% collagenase and 0.1% hyaluronidase in F-12 medium (43) . F1 and F3 cells were centrifuged separately at 150 ϫ g for 5 min and plated in 100-mm Falcon Primeria dishes at a density of 10,000 cells/cm 2 in modified F-12 medium with 5% horse serum, 2% FBS (Life Technologies, Inc.), and 100 g/ml kanamycin. F3 cells were shown to have increased ␣1(I) procollagen and alkaline phosphatase messenger RNA and increased collagen synthesis compared with F1 cells (our unpublished data). The phenotype of these fractions had been previously characterized (44) . Thus, F3 appears to be a population of osteoblast progenitors and young osteoblasts, whereas F1 are mainly fibroblasts. At confluence, the cells were trypsinized and plated at a density of 14,000 cells/cm 2 in phenol red-free F-12 medium with 1% serum and 100 g/ml kanamycin. After 24 h of preculture, cells were treated with varying doses of corticosterone (1-1000 nm), the endogenous glucocorticoid of the rat; estrogen (0.01-1.0 nm 17␤-estradiol and 0.1 nm 17␣-estradiol); or 10 g/ml lipopolysaccharide (Sigma Chemical Co., St. Louis, MO) in the presence of 0.2% serum. The low concentration of serum is required to maintain cell attachment to the culture plate.
In addition, mouse osteoblasts, F3, were obtained from 6-day-old mouse calvaria by a similar method of sequential digestion with 0.2% collagenase and 0.1% hyaluronidase in F-12 medium and cultured as described above for rat osteoblasts.
Acridine orange/ethidium bromide staining
Osteoblasts were cultured in four-well Nunc plates (Nunclon, Copenhagen, Denmark) at a density of 40,000 cells/well. The cells were labeled using the nucleic acid-binding dye mix of 100 g/ml acridine orange and 100 g/ml ethidium bromide (Sigma Chemical Co.) in PBS. The cells were examined by fluorescence light microscopy. Viable cells had green fluorescent nuclei with organized structure. The early apoptotic cells had yellow chromatin in nuclei that were highly condensed or fragmented. Apoptotic cells also exhibited membrane blebbing. The late apoptotic cells had orange chromatin with nuclei that were highly condensed and fragmented. The necrotic cells had bright orange chromatin in round nuclei. Only cells with yellow, condensed, or fragmented nuclei were counted as apoptotic cells in a blinded, nonbiased manner. For each sample, at least 500 cells/well and 4 wells/condition were counted, and the percentage of apoptotic cells was determined: % of apoptotic cells ϭ (total number of apoptotic cells/total number of cells counted) ϫ 100.
In vivo treatment of mice
Seven-day-old neonatal CD-1 mice (Charles River Laboratories, Inc., Boston, MA) were used for this study. Stock solutions of 1 mg/ml dexamethasone, 5 mg/ml 17␤-estradiol, and 5 mg/ml 17␣-estradiol were prepared in ethanol. Dosing solutions were prepared by diluting the stock solution with normal saline. After measuring their weight, mice were given daily sc injections of dexamethasone (0.1, 0.3, or 1.0 mg/kg BW) and/or 17␤-estradiol and/or 17␣-estradiol (0.5, 3, and 5 mg/kg BW). At 72 h, mice were weighed and killed. The entire calvarium was removed for histological, and terminal deoxynucleotidyltransferase-mediated deoxy-UTP-biotin nick end labeling (TUNEL) analysis. Six mice were used in each group, and the experiment was repeated at least three times.
TUNEL staining of apoptotic cells
To detect apoptosis in osteoblasts, immunochemical staining of DNA fragments by TUNEL was performed with the Oncor Apoptag Plus Kit (Oncor, Gaithersburg, MD). Briefly, calvaria were fixed with 10% neutral-buffered formalin for 24 h and then embedded in paraffin. The sections were subsequently cleared in xylene and digested with 5 g/ml proteinase K in 10 mm Tris-0.1 mm EDTA buffer for 15 min at room temperature. The residues of digoxigenin-nucleotide were added to the fragmented DNA by terminal deoxynuceotidyl transferase at 37 C for 1 h. The fragmented DNA was subsequently labeled with antidigoxigenin antibody conjugated to a fluorophore in a humidified chamber for 30 min at room temperature. The tissue sections were counterstained with propidium iodide/Antifade (Oncor). Apoptotic cells were visualized in a Nikon Optiphot microscope (Melville, NY).
After staining, static histomorphometric measurements were performed using the Bioquant program (Bioquant-True Color Windows, R & M Biometrics, Inc., Nashville, TN) in a blinded nonbiased manner. One section per animal was selected for the absence of tears or folding. The number of apoptotic cells, the total number of osteoblasts along the bone surface, and the perimeter of the bone (0.7-0.8 mm/section) were determined at ϫ20 magnification. Then, the percentage of apoptotic cells was determined as a percentage of apoptotic cells per total number of osteoblasts. For each treatment group, 3.2 mm bone surface were analyzed. For in vitro studies, cells were fixed in 2% paraformaldehyde for 30 min and then digested in 5 g/ml proteinase K for 10 min. The cells were stained similarly as the tissue samples. Each in vivo experiment had six animals per group and was repeated three times.
Western blot analysis
Protein was extracted from cell cultures with 10 mm Tris, 0.1% SDS, and protease inhibitors (1 g/ml leupeptin, 0.5 g/ml pepstatin, and 0.7 g/ml aprotonin) and measured with the bicinchoninic acid protein assay kit (Pierce Chemical Co., Rockford, IL). Seventy micrograms of protein per lane was loaded onto a 10 -20% SDS-polyacrylamide gel. Protein was electrophoretically transferred to Immobilon-P membranes (Millipore Corp., Bedford, MA) in 25 mm Tris base, 192 mm glycine, and 15% methanol (TBS; vol/vol). Membranes were blocked with 1% TBS containing 0.1% Tween (T-TBS) and 5% skim milk overnight at 4 C. After washing in T-TBS, blots were incubated for 1 h with either a 1:150 dilution of Bcl-2 or Bax rabbit polyclonal antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in blocking buffer, followed by 1 h with 1:20,000 dilution of goat antirabbit IgG conjugated to horseradish peroxidase in blocking buffer (Pierce Chemical Co.). Positive bands were identified using a Pierce Chemical Co. chemiluminescent kit and Fuji Photo Film Co. Ltd. film (Tokyo, Japan). After detection, the membranes were stripped by incubation in 100 mm 2-mercaptoethanol, 2% SDS, and 62.5 mm Tris, pH 6.8, for 45 min at 50 C, blocked, and then washed in T-TBS and reprobed. Western blots were performed three times.
Statistical analysis
Statistical analysis was performed by an one-way ANOVA, followed by Student-Newman-Keuls test to determine significance between groups. In the text, significant differences refer to P Ͻ 0.05.
Results
After treatment with glucocorticoids and/or estrogen, apoptotic rat osteoblast-like cells were visualized by acridine orange and ethidium bromide staining to determine cell morphology. Viable cells excluded the ethidium bromide, but were permeable to acridine orange, which intercalated into the DNA to yield green fluorescent nuclei. Vehicle-treated cells exhibited few if any apoptotic cells at 72 h (Fig. 1A) . Treatment with 100 nm corticosterone for 72 h produced apoptotic cells that had yellow chromatin in condensed nuclei and often had membrane blebbing (Fig. 1B) . Necrotic cells had orange nuclei, and there was no significant increase in the number of necrotic cells with glucocorticoid treatment. This was also confirmed by trypan blue exclusion. Simultaneous administration of 100 nm corticosterone and 0.01 nm 17␤-estradiol diminished the number of apoptotic osteoblasts (Fig. 1C) . Neither the administration of 17␤-estradiol nor 17␣-estradiol alone affected the number of apoptotic cells (data not shown).
A similar effect of glucocorticoids and estrogen on osteoblast apoptosis is seen with the TUNEL technique, which more specifically identifies apoptotic cells because it labels DNA fragments. However, due to the expense and loss of apoptotic cells from the culture dish with multiple rinses when performing TUNEL, it is more difficult to use for quantitation of apoptosis in cell culture. However, TUNEL is an excellent technique for visualizing apoptotic cells in tissues. Cultured rat apoptotic osteoblasts displayed condensed irregular nuclei that stained yellow-green and were often found in large aggregates as shown in Fig. 1E . Apoptotic osteoblasts were rarely seen in control cultures (Fig.  1D) . Treatment with 0.01 nm 17␤-estradiol prevented apoptosis in osteoblast cultures treated with 100 nm corticosterone (Fig. 1F) . No effect on the number of apoptotic cells was seen in glucocorticoid-treated cultures with 0.01 nm 17␣-estradiol or 17␤-estradiol (data not shown).
To quantitate the number of apoptotic cells at various time points, 100 nm corticosterone was administered for 24, 48, 72, and 96 h ( Fig. 2A) . A maximal effect was found at 72 h. Treatment with varying concentrations of corticosterone at 72 h demonstrated a dose-dependent effect with 100 nm corticosterone producing 31 Ϯ 2% apoptotic cells compared with 3.4 Ϯ 0.5% in control cultures (Fig. 2B ). Higher concentrations of corticosterone or longer incubations with corticosterone caused cell lifting of late apoptotic cells, which made it difficult to accurately quantitate apoptotic cells. Therefore, the number of apoptotic cells appeared to decrease on the culture dish at 96 h or with 1000 nm corticosterone (Fig. 2, A and B) . To determine the cell specificity of the glucocorticoid effect, fibroblastic F1 and osteoblastic F3 cells were treated with 100 nm corticosterone or vehicle for 72 h. In contrast to F3 cells, the F1 cells did not undergo glucocorticoid-induced apoptosis (Fig. 2C) . We also examined glucocorticoid's effect on primary mouse osteoblasts. Mouse osteoblasts, F3, demonstrated a similar dose-response curve as corticosterone; however, the maximal effect was 26 Ϯ 3% of apoptotic cells with 100 nm corticosterone at 72 h (Fig. 2D) .
Addition of various concentrations of 17␤-estradiol to corticosterone-treated osteoblastic cultures decreased apoptosis with a maximal decrease of approximately 70% with 0.1 nm 17␤-estradiol (Fig. 3) . Treatment with 1 nm 17␤-estradiol and 100 nm corticosterone inhibited glucocorticoid-induced apoptosis by approximately 57%. No significant change was seen with 17␣-estradiol. Estrogen also decreased the number of mouse apoptotic cells induced by glucocorticoids to the same extent as rat osteoblasts (data not shown).
The ability of estrogen to prevent apoptosis was also found with lipopolysaccharide-induced apoptosis. F3 cells were first treated with varying concentrations of lipopolysaccharide to determine which dose would produce apoptosis and maintain cell viability, as assayed be trypan blue exclusion. A concentration of 10 g/ml was optimal for inducing apoptosis as measured by acridine orange/ethidium bromide staining and maintaining 95-98% cell viability (data not shown). Control or vehicle-treated F3 murine osteoblasts had 4.4 Ϯ 0.6% apoptotic cells (Fig. 4) . Treatment of F3 murine osteoblasts with 10 g/ml lipopolysaccharide for 72 h caused apoptosis in 42.4 Ϯ 3.3% of the osteoblasts (Fig. 4) . Simultaneous treatment of cells with the same concentration of lipopolysaccharide and 0.1 nm 17␤-estradiol reduced apoptosis to 10.4 Ϯ 1.3%.
To determine how glucocorticoids may elicit apoptosis in osteoblasts, the levels of Bcl-2 and Bax protein were analyzed by Western blot. A typical Western blot is shown in the top panel of Fig. 5 , A-D, with the densitometric scans of three blots in the middle and the Bcl-2/Bax ratio of the three blots at the bottom of each graph. Cells were treated with varying concentrations of corticosterone for 72 h (Fig. 5A) . Corticosterone caused a dose-dependent decrease in the levels of Bcl-2 protein. Corticosterone at 100 and 1000 nm demonstrated significant reductions of 60% and 82% in Bcl-2 protein levels, respectively, compared with vehicle-treated cells. Corticosterone at 100 nm caused a significant 16% increase in Bax protein. Because the Bcl-2/Bax ratio determines whether a cell will undergo apoptosis (42), densitometric scans of the bands were performed to determine the mean ratio of Bcl-2 to Bax levels in cells treated with corticosterone or vehicle in three experiments. The Bcl-2/Bax ratio in control cells was arbitrarily set at 1. Corticosterone decreased the Bcl-2/Bax ratio, with a maximal decrease to 0.18 with 1000 nm.
The time course of the effect of 100 nm corticosterone on Bcl-2 and Bax was also analyzed by Western blot (Fig. 5B) . At 6 h, no significant difference in Bcl-2 was found in control vs. corticosterone-treated cells. However, Bax levels were increased significantly by 20.0 Ϯ 3.1%. By 12 h, a significant decrease of 54.4 Ϯ 2.0% was seen for Bcl-2. The graph of the densitometric scans of the Bcl-2 and Bax levels in Fig. 5 are the means of three separate experiments and showed that the average decrease in Bcl-2 was 51% at 24 h. For the three experiments the Bcl-2/Bax ratio in control cells at 6 h was arbitrarily set at 1. Corticosterone significantly decreased the Bcl-2/Bax ratio to 0.83 at 6 h and to 0.47 by 12 h, where it remained for 72 h. A time-dependent decrease in Bcl-2 and Bax levels in control cells was also seen in Western blots, perhaps due to the presence of only 0.2% serum in these primary osteoblast cultures.
The effect of estrogen on Bcl-2 and Bax levels were examined in F3 cells at 72 h (Fig. 5C ). Corticosterone (100 nm) significantly decreased Bcl-2 levels by 58%, whereas 17␤-estradiol alone and 17␣-estradiol alone had no effect on Bcl-2 levels. Treatment of osteoblastic cells with 0.1 nm 17␤-estradiol and 100 nm corticosterone blocked the corticosteroneinduced decrease in Bcl-2 protein levels. The increase in Bax protein after glucocorticoid treatment was also prevented by simultaneous treatment with estrogen. The Bcl-2/Bax ratio, which was reduced to 0.37 in glucocorticoid-treated cells, increased to 1.19 with administration of 17␤-estradiol. In contrast, 17␣-estradiol had no effect on glucocorticoid-induced apoptosis. Thus, 17␤-estradiol prevented the glucocorticoid-induced decrease in the Bcl-2/Bax ratio. Analysis of Western blots for Bcl-2 and Bax levels in F1 cell cultures also demonstrated that F1 cells did not undergo apoptosis in response to glucocorticoids or estrogen (Fig.  5D) . These results also confirmed data obtained by histology, as illustrated in Fig. 2C .
As it has been shown that 1 mg/kg BW dexamethasone suppresses bone collagen synthesis at 24 h in neonatal mice (45), 7-day-old mice were injected with dexamethasone to study the effect of glucocorticoids on osteoblast apoptosis. Mice were injected sc with dexamethasone (0.1, 0.3, and 1 mg/kg BW) or vehicle, 17␤-estradiol, and/or 17␣-estradiol for 72 h. To determine the population of cells in mouse calvaria that undergoes apoptosis after dexamethasone treatment, staining of fragmented DNA was performed by the TUNEL technique (Fig. 6) . In situ staining of calvaria demonstrated apoptosis in the mature osteoblasts lining the mineralized matrix in mice treated with 0.3 mg/kg BW (Fig. 6B ) and 1 mg/kg BW (Fig. 6C) dexamethasone for 72 h compared with control (Fig. 6A) . Usually apoptotic osteoblasts were seen as a contiguous layer along the bone, as shown in Fig.  6C . Apoptotic cells were rarely seen in the periosteum. In sutures of the neonatal mouse calvaria where the periosteum is thicker by several cell layers, no increase in TUNEL-labeled periosteal cells was seen with dexamethasone (data not shown). In addition, no apoptotic cells were seen among the osteocytes. With 5 mg/kg BW 17␤-estradiol and 1 mg/kg BW dexamethasone, a decrease in apoptotic osteoblasts was apparent, and few apoptotic osteoblasts were seen (Fig. 6D) . Neither 17␤-estradiol alone (Fig. 6E ) nor 17␣-estradiol alone (not shown) had any visible effect on the number of apoptotic cells. In mice treated with 1 mg/kg BW dexamethasone for 72 h (Fig. 7) , quantitation of TUNEL-labeled osteoblasts demonstrated an approximately 8-fold increase in the number of apoptotic osteoblasts (21.6 Ϯ 1.5%) along the bone surface of the calvaria compared with that in vehicle-treated mice (2.2 Ϯ 0.7%). With 0.3 mg/kg BW dexamethasone, a 4-to 5-fold increase in apoptotic osteoblasts was seen, whereas 0.1 mg/kg BW had a small, but insignificant, effect at 72 h (data not shown). The average length of the osteoblast on the bone surface was 8.4 m, which did not vary significantly with treatment. Seven-day-old mice were injected with 1 mg/kg BW dexamethasone and varying concentrations (0.5, 3, and 5 mg/kg BW) of 17␤-estradiol or 17␣-estradiol (Fig. 7) . A dose-dependent decrease in the number of apoptotic osteoblasts induced by glucocorticoids was found with 3 mg/kg BW 17␤-estradiol producing a significant decrease and 5 mg/kg BW 17␤-estradiol reducing the number (4.8 Ϯ 0.9%) almost to vehicle-treated levels at 72 h. In contrast, 17␣-estradiol alone or with dexamethasone had no significant effect. 
Discussion
We have demonstrated that estrogen prevents glucocorticoid-induced apoptosis of osteoblasts both in vitro and in vivo. Glucocorticoid-induced apoptosis was dependent on the concentration of glucocorticoids with the maximum effect at 100 nm corticosterone and 72 h in both rat and mouse osteoblast cultures. Glucocorticoid-induced apoptosis could be prevented by simultaneous administration of 17␤-estradiol both in vivo and in vitro. In contrast, 17␣-estradiol had no effect. Glucocorticoids reduced Bcl-2 levels and increased Bax protein levels by 12 h of treatment in murine osteoblast cultures, resulting in a dramatic decrease in the Bcl-2 to Bax ratio, which is involved in regulating apoptosis. The reduction in Bcl-2/Bax could be prevented by treating osteoblasts simultaneously with varying concentrations of 17␤-estradiol (0.1-1.0 nm).
In humans, the concentration of cortisol is 220 -600 nmol/ liter, and this level is greater with high dose glucocorticoid therapy, although glucocorticoid-binding proteins in the serum lower the effective concentration (46) . In 21-day-old rats, the serum concentration of its natural glucocorticoid, corticosterone, is 0.3 m (14). Therefore, 1-100 nm corticosterone is supraphysiological, but may be pertinent to the in vivo state of patients receiving high dose glucocorticoid therapy. The levels of estradiol in humans is 7-220 pmol/liter, with an ovulatory surge resulting in concentrations of greater than 740 pmol/liter (46) . In our studies, the most effective dose of 17␤-estradiol in preventing apoptosis was 0.1-0.01 nm; therefore, this dose is physiologically relevant.
Glucocorticoid-induced apoptosis appears to be specific for osteoblasts from both mouse and rat cell cultures. Glucocorticoids failed to induce apoptosis in fibroblastic F1 cells derived from fetal rat calvaria, as demonstrated by acridine orange/ethidium bromide staining and Western blot analysis of Bcl-2 and Bax levels. In contrast, F3 cells, which are known to be osteoblast-like and respond to PTH, underwent apoptosis (43) . In addition, corticosterone with or without 17␤-estradiol had no significant effect on Bcl-2 or Bax levels in appeared to have no significant effect on periosteal cells in vivo. The finding of a glucocorticoid-specific effect on osteoblasts and not fibroblasts is supported by previous work in our laboratory demonstrating the corticosterone decreases cell attachment and fibronectin integrin levels in F3, but not F1 cells (47, 48) . As the fibronectin integrin, ␣ 5 ␤ 1 , has been shown by others to be important in cell survival, and its down-regulation induces apoptosis (49), these results suggest that integrins may be involved in the apoptotic pathway induced by glucocorticoids. In contrast to Weinstein et al. (30) , we did not see any apoptotic osteocytes. This may be explained by differences in the glucocorticoid used (prednisolone vs. corticosterone) and/or the dose and duration of treatment (27 days vs. 3 days in our system). In addition, osteocyte apoptosis was restricted to a small group of cells in the center of the metaphysis of the femur, according to Weinstein et al. (30) . They were absent from vertebral cortical bone, even though apoptotic osteoblasts were found. Therefore, our combined data suggest that a primary target for glucocorticoid-induced apoptosis in the bone cell lineage is the osteoblast.
Glucocorticoid treatment also failed to induce apoptosis in transformed or immortalized osteoblast-like lines such as Saos-2 cells, ROS 17/2.8 cells, and MC3T3 cells (our unpublished data), which suggests that the glucocorticoid effect is specific for primary, untransformed osteoblasts. Thus, it appears that normal cell function and signaling are necessary for glucocorticoid-induced apoptosis in osteoblasts. Perhaps a factor is altered by transformation and thereby prevents transformed cells from undergoing apoptosis.
Estrogen protects osteoblasts from apoptosis, as it not only prevented apoptosis induced by glucocorticoids but also that caused by lipopolysaccharide treatment. Pretreatment of osteoblasts with 17␤-estradiol for 1 h further reduced the number of glucocorticoid-induced apoptotic cells compared with that in cells treated with glucocorticoids and estrogen simultaneously in murine osteoblasts (our unpublished data). Thus, future experiments will involve pretreatment of osteoblasts with estrogen for varying times to prevent completely glucocorticoid-induced apoptosis. The effect of estrogen also appears to be mediated through the classical steroid receptor for estrogen, as the inactive isomer of estrogen, 17␣-estradiol, did not affect the number of apoptotic cells produced by glucocorticoids in vitro or in vivo. As estrogen also has the ability to promote osteoclast apoptosis (34, 35) , regulation of the life span of bone cells may be one of the mechanisms by which estrogen affects bone remodeling and bone mass.
Apoptosis was commonly found in neighboring osteoblasts. In bone, specific groups of contiguous osteoblasts lining the mineralized matrix exhibited apoptosis with glucocorticoid treatment, whereas most of the osteoblasts appeared viable. The focal localization of apoptotic cells has also been found in neighboring cells in the tip of villus epithelium of normal intestine (50) . As osteoblasts are known to communicate with each other and osteocytes through gap junctions, factors involved in apoptosis in one osteoblast may be able to stimulate apoptosis in neighboring osteoblasts and osteocytes. In cell cultures stained with acridine orange/ ethidium bromide or TUNEL, apoptosis was most apparent in semiconfluent cultures where small aggregates of cells exhibited DNA fragmentation, as shown in Fig. 1 . However, individual apoptotic cells were also apparent amid viable cells. These aggregates of apoptotic cells would often detach from their substrate, especially with the TUNEL technique, which requires numerous washing steps. Cell adhesion receptors, such as integrins, have been shown to be involved in fibroblast apoptosis, and loss of integrin-mediated attachment of the fibronectin integrin can induce apoptosis (49) , which may also be occurring in osteoblast cultures.
In this study, estrogen reversed the glucocorticoid-induced decrease in the Bcl-2/Bax ratio. As Bcl-2 levels remain elevated with estrogen treatment, estrogen may prevent apoptosis induced by other factors besides lipopolysaccharides, such as aging, growth factor depletion, and UV radiation. Interestingly, a time-dependent decrease in Bcl-2 and Bax levels in control cells was seen with Western blots, probably due to the presence of only 0.2% serum in these primary osteoblast cultures, which are serum dependent for survival. Or, Bcl-2 and Bax levels may be induced when cells are trypsinized and replated in culture, and once they attach, spread, and proliferate, their levels decrease. With a low level of serum, F3 cells are viable for at least 2 weeks and then start to lift from the dish. In B cells and other tissues, the Bcl-2 protein appears to protect cells from undergoing apoptosis in response to many stimuli (51). Bcl-2 protects cells from apoptosis by binding to the proapoptotic proteins, such as Bax, Bcl-xs, and Bad; thus, it is the Bcl-2/Bax ratio that plays an important role in determining a cell's fate (42, 53) . When the level of Bcl-2 is high, Bcl-2 homodimers and Bcl-2/ Bax heterodimers predominate, and cells survive. When the level of Bcl-2 is low and/or the level of Bax is high, Bax homodimers predominate, and cells undergo apoptosis. Programmed cell death has been shown to be prevented by increasing Bcl-2 levels in numerous cell types by transfection or other molecular techniques (53, 54) . Acridine orange/ethidium bromide staining of glucocorticoid-treated osteoblast cultures demonstrated that the decrease in the Bcl-2/Bax ratio preceded DNA fragmentation visualized by 48 h. The Bcl-2 levels were decreased by 54% at 12 h, and Bax levels were up-regulated as early as 6 h, suggesting that the Bcl-2/Bax ratio may play an important role in osteoblast survival. In rats, a dose of 5 mg/kg dexamethasone injection can induce DNA fragmentation in thymocytes as early as 2 h after steroid treatment (56) .
Estrogen has been shown to be effective in preventing osteoporosis (9) . Long term estrogen treatment has been shown to reduce the incidence of fractures of vertebrae, distal forearm, and hip by 50% (57, 58) . Estrogen has been shown to promote apoptosis of murine osteoclasts in vitro and in vivo (35) , thus inhibiting bone resorption and reducing bone loss. The differential effect of estrogen on osteoblasts vs. osteoclasts has precedence in other cell types and with other hormones, such as the effect of glucocorticoids on apoptosis of lymphoid cells, which is not only cell type specific but also cell stage specific (56) . Our data suggest that another beneficial effect of estrogen may be to prolong the life of the osteoblast on the bone surface.
